



CAPITAL VALMORIS INC. ("VALMORIS"), BIOTONIX INC. ("BIOTONIX") AND SYLVAIN GUIMOND ("GUIMOND") ANNOUNCE THE CLOSING OF THEIR QUALIFYING TRANSACTION AND \$2,500,000 PUBLIC FINANCING OF VALMORIS

(Boucherville, March 18, 2010) – Valmoris (TSX-V:VMO.P) announced today the issuance of 8,750,000 common shares at \$0.40 per share pursuant to the closing of the qualifying transaction between Biotonix and Guimond.

Valmoris, which changed its name to Biotonix (2010) Inc. upon closing of the transaction, also announced that it has concluded a financing of 6,250,000 Units for a total consideration of \$2,500,000, as per the terms and conditions of its final prospectus dated February 16, 2010 (the "Prospectus").

Each Unit consists of one common share of Valmoris at \$0.40 per share and one-half warrant, each whole warrant entitling the holder to subscribe to one common share of Valmoris at a price of \$1.00 until March 18, 2012.

Industrielle Alliance valeurs mobilières Inc. acted as agent for the purposes of the transaction and received a cash remuneration of \$225,000 as well as 437,500 warrants entitling it to acquire a maximum of 437,500 common shares at a price of \$0.40 per share until March 18, 2012.

At the conclusion of these transactions, Biotonix (2010) Inc.'s cash position will stand at \$2,380,000. The funds will primarily be used to pursue Biotonix's current activities, as well as research and development efforts on orthotic technologies for the back and foot.

Biotonix (2010) Inc. also announces that a total of 460,000 options have been issued to certain directors and executive members upon the closing, as disclosed in its Prospectus. The options have an exercise price of \$0.40 per share and will come to maturity on March 18, 2020. Biotonix (2010) Inc. further announces the appointment to its Board of Directors of Mr. François Côté, Executive Vice President and President of TELUS Health Solutions and TELUS Québec. At the closing date, Mr. Côté received 70,000 options at an exercise price of \$0.40 and maturing on March 18, 2020.

In addition, Biotonix (2010) Inc. announced the appointment of Mrs. Louise St-Onge as Chief Executive Officer; Mr. François Poulin as Vice President, R&D, Strategic Marketing and New Product Launches; and Mrs. Julie M. Thibodeau as Vice President, Corporate Communications and Investor Relations. At the closing date, these appointees received 100,000, 20,000 and 20,000 options respectively, at an exercise price of \$0.40 and maturing on March 18, 2020.

At the closing date, Biotonix (2010) Inc. announces as well the creation of an Advisory Committee comprised of Mr. Mario Lemieux, one of the principal owners and Chairman of the Pittsburgh Penguins; Mr. Jacques Ménard, Chairman, BMO Nesbitt Burns and President, BMO Financial Group, Québec; Mr. Pat Brisson, Co-Head, CAA Sports, Creative Artists Agency; Dr. Marc J. Philippon, Orthopedic Surgeon at the Steadman



Hawkins Clinic; and Dr. Pierre Ranger, Orthopedic Surgeon at Montreal's Sacré-Coeur Hospital. Each member of the Committee received 50,000 options at the closing date, subject to an exercise price of \$0.40 and maturing on March 18, 2020.

In addition, Biotonix (2010) Inc. signed a contract with Mr. Mario Lemieux, one of the principal owners and Chairman of the Pittsburgh Penguins, who will act as the official spokesperson for the Company. Under the contract terms, 250,000 options at an exercise price of \$0.40 and maturing on March 18, 2013 were issued to Mr. Lemieux. A further 250,000 options will be issued at market price on March 18, 2011 and will mature on March 18, 2014.

Finally, trading of Biotonix (2010) Inc. shares will begin at market opening on March 24, 2010 under the ticker BTX.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

BIOTONIX PROFILE

Biotonix offers innovative health solutions for posture correction using a web-based imaging software technology. Biotonix is currently developing novel orthotics for the back and foot, also geared specifically toward improving posture. For more information please visit

www.biotonix.com

- 30 -

For additional information, please contact:

Dr. Sylvain Guimond, D.O., Ph.D.
President and Founder, Biotonix (2010) Inc.
Phone: (514) 840-0004

Mr. Yves Morissette
President, Capital Valmoris Inc.
Phone: (450) 655-1887

Mrs. Julie M. Thibodeau, B.Sc., MBA
VP, Corporate Communications and Investor Relations, Biotonix (2010) Inc.
Phone: (514) 840-0004 x223
thibodeauj@biotonix.com